Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00069277
First received: September 19, 2003
Last updated: April 6, 2012
Last verified: April 2012
  Purpose

The malignancies (advanced solid tumors) that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity, both in vitro and in vivo. The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these, and potentially other, tumor types.


Condition Intervention Phase
Cancer
Drug: E7389
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Changes in Only the Largest Diameter of the Tumor Lesions Are Used. [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]

Enrollment: 21
Study Start Date: August 2003
Study Completion Date: April 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a histologically or cytologically confirmed and measurable advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy)
  • Patients may have received prior chemotherapy (limit of two prior chemotherapy regimens)
  • Patients must be aged >= 18 years
  • Patients must have a Karnofsky Performance Status of > 70% -- Patients must have a life expectancy of > 3 months
  • Patients must have adequate renal function as evidenced by serum creatinine <1.5 mg/dL or creatinine clearance > 60 mL/minute
  • Patients must have adequate bone marrow function as evidenced by absolute neutrophil count > 1,500/µL and platelets > 100,000/µL
  • Patients must have adequate liver function as evidenced by bilirubin < 1.5 mg/dL and alanine transaminase (ALAT) and aspartate transaminase (ASAT) < 2 times the upper limits of normal
  • Patients must be willing and able to comply with the study protocol for the duration of the study
  • Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria:

  • Patients who have received chemotherapy within three weeks (six weeks if nitrosoureas were received) of E7389 treatment start
  • Patients who have not recovered from any chemotherapy related or other therapy related toxicity at study entry
  • Patients who require therapeutic doses of anti-coagulant therapy (eg, Coumadin, heparin, low molecular weight heparin). Low doses of anticoagulants used for patency (e.g., lines, catheters, ports) are permitted.
  • Women who are pregnant or breastfeeding.
  • Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential)
  • Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception
  • Patients who have not successfully completed local therapy for previously treated central nervous system (CNS) metastases and who have not been discontinued from corticosteroids for at least four weeks before starting treatment with E7389. Patients with asymptomatic brain metastases who have no evidence of midline shift on CT scan or MRI may be enrolled without initiation of local therapy for the CNS metastases. In this case, a repeat scan must be performed within four weeks of the original scan to ensure that disease progression is not occurring.
  • Patients who have tested positive for HIV
  • Patients with severe uncontrolled intercurrent illness/infection (excluding malignancies)
  • Patients with cardiovascular impairment
  • Patients with organ allografts
  • Patients who have received investigational drugs, including immunotherapy, gene therapy, hormone therapy, or other biologic therapy; anti-neoplastic therapy; or radiation therapy (other than required for palliation) within three weeks of E7389 treatment start
  • Patients who have had major surgery within four weeks of E7389 treatment start without a full recovery
  • Patients with a hypersensitivity to Halichondrin B and/or Halichondrin B-like compounds Patients with other significant disease that, in the Investigator's opinion, would exclude the patient from the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00069277

Locations
United States, California
Cancer Institute Medical Group
Los Angeles, California, United States, 90025
Premiere Oncology
Santa Monica, California, United States, 90404
United States, New Jersey
New Brunswick, New Jersey, United States, 08901
Sponsors and Collaborators
Eisai Inc.
Investigators
Study Director: Dale Schuster, Ph.D Eisai Inc.
  More Information

No publications provided

Responsible Party: Dale Shuster, Ph.D, Eisai Medical Research
ClinicalTrials.gov Identifier: NCT00069277     History of Changes
Other Study ID Numbers: E7389-A001-102
Study First Received: September 19, 2003
Results First Received: January 9, 2012
Last Updated: April 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Eisai Inc.:
Cancer, tumors

ClinicalTrials.gov processed this record on October 23, 2014